Collegium Pharmaceutical
COLL
140 hedge funds and large institutions have $773M invested in Collegium Pharmaceutical in 2018 Q1 according to their latest regulatory filings, with 47 funds opening new positions, 37 increasing their positions, 41 reducing their positions, and 8 closing their positions.
488% more first-time investments, than exits
New positions opened: 47 | Existing positions closed: 8
150% more funds holding in top 10
Funds holding in top 10: 2 → 5 (+3)
47% more capital invested
Capital invested by funds: $526M → $773M (+$247M)
39% more funds holding
Funds holding: 101 → 140 (+39)
4.44% more ownership
Funds ownership: 87.53% → 91.97% (+4.4%)
10% less repeat investments, than reductions
Existing positions increased: 37 | Existing positions reduced: 41
42% less call options, than puts
Call options by funds: $1.29M | Put options by funds: $2.25M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Macquarie Group
Sydney, NSW 2000,
Australia
|
+$17.6M |
| 2 |
Janus Henderson Group
London,
United Kingdom
|
+$12.8M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$9.23M |
| 4 |
State Street
Boston,
Massachusetts
|
+$5.88M |
| 5 |
JGC
J. Goldman & Co
New York
|
+$5.34M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$12.4M |
| 2 |
First Manhattan
New York
|
-$11.1M |
| 3 |
HCMT
Highland Capital Management (Texas)
Dallas,
Texas
|
-$6.58M |
| 4 |
SAM
Sectoral Asset Management
Montreal,
Quebec, Canada
|
-$4.53M |
| 5 |
TGHSA
TPG Group Holdings (SBS) Advisors
Fort Worth,
Texas
|
-$3.92M |
COLL Hedge Fund Activity: Q1 2018 in Review
140 of the 4,364 institutional investors tracked by Wall St. Rank reported a position in Collegium Pharmaceutical (COLL) for Q1 2018, worth a combined $773M — up 47% from $526M a quarter earlier.
Buyers outnumbered sellers: 47 funds opened new COLL positions and 8 closed out — a net gain of 39 holders — while 37 added to existing stakes and 41 trimmed.
The largest buyer was Macquarie Group, adding an estimated $17.6M. The largest seller was Citadel Advisors, cutting an estimated $12.4M.
- 140 institutional investors held Collegium Pharmaceutical (COLL) as of Q1 2018, up from 101 in Q4 2017.
- Funds reported $773M of Collegium Pharmaceutical stock for Q1 2018, up 47% quarter-over-quarter.
- 47 funds opened new Collegium Pharmaceutical positions in Q1 2018 and 8 closed out, a net change of +39 holders.
- The largest Collegium Pharmaceutical buyer in Q1 2018 was Macquarie Group, an estimated $17.6M added.
- The largest Collegium Pharmaceutical seller in Q1 2018 was Citadel Advisors, an estimated $12.4M sold.
Based on aggregated 13F filings for Q1 2018.